2021-08-13 | Abstract for Orviglance comparison study to gadolinium accepted at the world’s largest radiology conference RSNA PDF Report Presentation Webcast
2021-08-10 | Ascelia Pharma receives conditional FDA acceptance for brand name Orviglance PDF Report Presentation Webcast
Regulatory 2021-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021 PDF Report Presentation Webcast
Regulatory 2021-04-15 | Ascelia Pharma AB publishes prospectus regarding admission to trading of newly issued shares on Nasdaq Stockholm PDF Report Presentation Webcast
Regulatory 2021-04-13 | Bulletin from the extraordinary general meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2021-04-09 | Issue and repurchase of series C shares for share saving program PDF Report Presentation Webcast
Regulatory 2021-03-31 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
Regulatory 2021-03-17 | Notice of extraordinary general meeting in Ascelia Pharma PDF Report Presentation Webcast
2021-03-02 | Ascelia Pharma opens US office in preparation for Mangoral launch PDF Report Presentation Webcast
2021-01-12 | Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy PDF Report Presentation Webcast
Regulatory 2020-12-15 | Ascelia Pharma gets US patent for second generation Mangoral PDF Report Presentation Webcast
Regulatory 2020-12-02 | New study shows Mangoral’s lesion visualization as effective as gadolinium contrast agent PDF Report Presentation Webcast
2020-11-03 | EMA confirms Mangoral eligible for the centralized regulatory procedure in the EU PDF Report Presentation Webcast
Regulatory 2020-10-21 | Upgraded estimate of addressable market for Mangoral to $500-600 million annually PDF Report Presentation Webcast
2020-09-30 | Invitation to Ascelia Pharma’s virtual Capital Markets Day PDF Report Presentation Webcast
2020-06-09 | Presentation of Ascelia Pharma at ABGSC Life Science Summit Day and Redeye Orphan Drug Day PDF Report Presentation Webcast
2020-05-26 | Vator Securities: Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged. PDF Report Presentation Webcast
